First Institute of All Medicines
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, First Institute of All Medicines sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
First Institute of All Medicines: 6 sponsored US clinical trials, 4 recruiting.
First Institute of All Medicines sponsors 6 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 2 completed. The most-studied condition in this pipeline is Increase the Total Number of Stem Cells, with 1 trials.
Upper-quartile sponsor footprint
First Institute of All Medicines sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
6 total, page 1 of 1
A Randomized Double-Blinded and Placebo-Controlled Trial to Assess the Efficacy of Biophoton Therapy to Treat Type 2 Diabetes
NCT07124208
Impact of Biophoton Therapy on Chronic Severe Arthritis Pain
NCT06915012
The Impact of Biophoton Therapy on Self-Grown Stem Cells
NCT06855459
Impact of a Biophoton Therapy on Patients With Brain Disorders
NCT06147999
Can Patients With Chronic Stroke Regain Living Independence by Daily Energizing With Biophoton Generators
NCT06049849
Impact of Biophoton Generator on Chronic-Stroke Patients' Recovery
NCT05898334
What is open in the First Institute of All Medicines pipeline
4 recruiting of 6 indexed (67% open); 2 completed (33%).
Phase labels are sparse on this sponsor index, so phase mix is not charted here.
Top condition: Increase the Total Number of Stem Cells (1 trial), 5 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
First Institute of All Medicines: open-pipeline peers nationwide
Peers matched on 6 registered trials and 67% open enrollment, not the therapeutic-area sidebar.
First Institute of All Medicines sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 trials (± recruiting share)
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors near 67% open enrollment (± trial volume)
- ABL Bio · 67% recruiting · 3 trials
- Accelerated Cure Project for Multiple Sclerosis · 67% recruiting · 3 trials
- Advanced Reconstructive Surgery Alliance · 67% recruiting · 3 trials
- Alexander B Olawaiye, MD · 67% recruiting · 3 trials
Related
What to do with this First Institute of All Medicines page
6 registered trials is a research-attention snapshot, not an endorsement of First Institute of All Medicines or any single study.
- 4 of First Institute of All Medicines's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Increase the Total Number of Stem Cells is the condition First Institute of All Medicines studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Increase the Total Number of Stem Cells trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
First Institute of All Medicines pipeline card: 6 registered trials from official public datasets.Report a data error.